Clinical Trial Update: Evolution of Albumin on AOA1 Patients Supplemented With Coenzyme Q10 [Phase 3]

View source ↗

Summary

Phase 3 trial assessing albumin evolution in patients with ataxia-oculomotor apraxia type 1 who received Coenzyme Q10 has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ataxia-oculomotor Apraxia Type 1

Drugs mentioned

• Albumin
• Coenzyme Q10 (Coenzyme Q10)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Ataxia-oculomotor Apraxia 1 | Phase 3 | Status: COMPLETED